A RAIR–ATC transcriptional axis and multimodal drug-response modelling reveal class-level vulnerabilities in thyroid cancer

Siying Wang, Dechun Zhang, Weixuan Liu, Mengqian Zhu, Rongfang Li, Zhenyu Liu, Pei Wu, Tianyu Liu · 2026

Read A RAIR–ATC transcriptional axis and multimodal drug-response modelling reveal class-level vulnerabilities in thyroid cancer by Siying Wang, Dechun Zhang, Weixuan Liu, Mengqian Zhu, Rongfang Li, Zhenyu Liu, Pei Wu, Tianyu Liu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13223037.txt.

Description

Siying Wang and seven co-authors published a 2026 study linking two hard thyroid cancer states through one gene program, in search of drug weaknesses. Radioiodine-refractory papillary cancer and anaplastic cancer are the deadliest forms of the disease. Merging many gene data cohorts, the team distilled a shared signature of the two states, built on tissue remodeling, blood vessel, and inflammation programs.

The signature graded tumors smoothly and traveled well to cell lines. In a large drug-response database, vessel-growth and RAF-pathway drug classes hit signature-high lines hardest. A combined prediction model beat simpler baselines. One drug, sorafenib, validated the pattern in a lab model, killing cells dose by dose and damping the predicted pathway. The authors offer the signature as a therapy-picking aid.

Catalog record

CREATORSiying Wang, Dechun Zhang, Weixuan Liu, Mengqian Zhu, Rongfang Li, Zhenyu Liu, Pei Wu, Tianyu Liu
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE80 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13223037

Browse the full library · About the Tower of Babel